Francesca M. Cook
Nessuna posizione attualmente
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Mack Gill | M | 72 |
PharmAthene, Inc. /Old/
PharmAthene, Inc. /Old/ BiotechnologyHealth Technology PharmAthene, Inc. develops biotherapeutics to address biological pathogens and chemicals. It provides clinical and preclinical development for Bacillus anthracis a therapeutic anti-toxin for treatment of symptomatic patients infected with anthrax monoclonal. The company was founded in 2001 and is located in Annapolis, MD.
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | 13 anni |
Joel W. McCleary | M | 75 |
PharmAthene, Inc. /Old/
PharmAthene, Inc. /Old/ BiotechnologyHealth Technology PharmAthene, Inc. develops biotherapeutics to address biological pathogens and chemicals. It provides clinical and preclinical development for Bacillus anthracis a therapeutic anti-toxin for treatment of symptomatic patients infected with anthrax monoclonal. The company was founded in 2001 and is located in Annapolis, MD.
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | 14 anni |
Philip MacNeill | M | 70 |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | - |
Jeff Jones | M | 52 |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | 10 anni |
Derace L. Schaffer | M | 76 |
PharmAthene, Inc. /Old/
PharmAthene, Inc. /Old/ BiotechnologyHealth Technology PharmAthene, Inc. develops biotherapeutics to address biological pathogens and chemicals. It provides clinical and preclinical development for Bacillus anthracis a therapeutic anti-toxin for treatment of symptomatic patients infected with anthrax monoclonal. The company was founded in 2001 and is located in Annapolis, MD.
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | 2 anni |
Christopher C. Camut | M | 61 |
PharmAthene, Inc. /Old/
PharmAthene, Inc. /Old/ BiotechnologyHealth Technology PharmAthene, Inc. develops biotherapeutics to address biological pathogens and chemicals. It provides clinical and preclinical development for Bacillus anthracis a therapeutic anti-toxin for treatment of symptomatic patients infected with anthrax monoclonal. The company was founded in 2001 and is located in Annapolis, MD.
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | - |
Jordan P. Karp | M | 57 |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD.
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 9 anni |
Mitchel Sayare | M | 76 |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | - |
Steven St. Peter | M | 57 |
PharmAthene, Inc. /Old/
PharmAthene, Inc. /Old/ BiotechnologyHealth Technology PharmAthene, Inc. develops biotherapeutics to address biological pathogens and chemicals. It provides clinical and preclinical development for Bacillus anthracis a therapeutic anti-toxin for treatment of symptomatic patients infected with anthrax monoclonal. The company was founded in 2001 and is located in Annapolis, MD.
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | 3 anni |
Jeffrey Runge | M | 67 |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | - |
Linda L. Chang | F | 57 |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | 4 anni |
Valerie D. Riddle | M | 63 |
PharmAthene, Inc. /Old/
PharmAthene, Inc. /Old/ BiotechnologyHealth Technology PharmAthene, Inc. develops biotherapeutics to address biological pathogens and chemicals. It provides clinical and preclinical development for Bacillus anthracis a therapeutic anti-toxin for treatment of symptomatic patients infected with anthrax monoclonal. The company was founded in 2001 and is located in Annapolis, MD.
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | 4 anni |
Wayne I. Roe | M | 73 |
Covance Health Economics & Outcomes Services, Inc.
| 11 anni |
Wayne Morges | M | 76 |
PharmAthene, Inc. /Old/
PharmAthene, Inc. /Old/ BiotechnologyHealth Technology PharmAthene, Inc. develops biotherapeutics to address biological pathogens and chemicals. It provides clinical and preclinical development for Bacillus anthracis a therapeutic anti-toxin for treatment of symptomatic patients infected with anthrax monoclonal. The company was founded in 2001 and is located in Annapolis, MD.
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | 10 anni |
David P. Wright | M | 75 |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD.
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 6 anni |
Brian Markison | M | 64 |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | 4 anni |
Donald W. Fallon | M | 69 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 2 anni |
Solomon Langermann | M | 64 |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD.
PharmAthene, Inc. /Old/
PharmAthene, Inc. /Old/ BiotechnologyHealth Technology PharmAthene, Inc. develops biotherapeutics to address biological pathogens and chemicals. It provides clinical and preclinical development for Bacillus anthracis a therapeutic anti-toxin for treatment of symptomatic patients infected with anthrax monoclonal. The company was founded in 2001 and is located in Annapolis, MD. | 3 anni |
Michael Kelly | M | 59 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 3 anni |
Susan Linna | F | - |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | - |
Charles Reinhart | M | 63 |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | 2 anni |
Arthur Y. Elliott | M | 88 |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | - |
Kevin Connolly | M | - |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | - |
Kimberly Taylor | M | - |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | - |
Alexander Sapir | M | 57 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 2 anni |
Richard Schoenfeld | M | - |
PharmAthene, Inc. /Old/
PharmAthene, Inc. /Old/ BiotechnologyHealth Technology PharmAthene, Inc. develops biotherapeutics to address biological pathogens and chemicals. It provides clinical and preclinical development for Bacillus anthracis a therapeutic anti-toxin for treatment of symptomatic patients infected with anthrax monoclonal. The company was founded in 2001 and is located in Annapolis, MD. | 2 anni |
John Pappajohn | M | 96 |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | 4 anni |
Joan Fusco | M | 68 |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | - |
Wayne A. Schellhammer | M | 70 |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | 2 anni |
Matthew Kinley | M | 56 |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | - |
Edward B. Berger | M | 95 |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | 2 anni |
Elizabeth Czerepak | F | 58 |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | 4 anni |
Thomas R. Fuerst | M | 67 |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | 2 anni |
Ansbert Gadicke | M | 66 |
PharmAthene, Inc. /Old/
PharmAthene, Inc. /Old/ BiotechnologyHealth Technology PharmAthene, Inc. develops biotherapeutics to address biological pathogens and chemicals. It provides clinical and preclinical development for Bacillus anthracis a therapeutic anti-toxin for treatment of symptomatic patients infected with anthrax monoclonal. The company was founded in 2001 and is located in Annapolis, MD. | 3 anni |
Ronald W. Kaiser | M | 70 |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | 1 anni |
Peter David Suzdak | M | 65 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 7 anni |
James Cavanaugh | M | 87 |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | 4 anni |
Marc A. Cohen | M | 61 |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | 1 anni |
Zhong Zhao | M | 57 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 6 anni |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Stati Uniti | 39 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Francesca M. Cook
- Contatti personali